The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
Open accessAbstract
BACKGROUND: In efficacy trials of a tetravalent dengue vaccine (CYD-TDV), excess hospitalizations for dengue were observed among vaccine recipients 2 to 5 years of age. Precise risk estimates according to observed dengue serostatus could not be ascertained because of the limited numbers of samples collected at baseline. We developed a dengue anti-nonstructural protein 1 (NS1) IgG enzyme-linked immunosorbent assay and used samples from month 13 to infer serostatus for a post hoc analysis of safety and efficacy. METHODS: ), with imputation conducted with the use of covariates that included the month 13 anti-NS1 assay results. The risk of hospitalization for virologically confirmed dengue (VCD), of severe VCD, and of symptomatic VCD according to dengue serostatus was estimated by weighted Cox regression and targeted minimum loss-based estimation. RESULTS: Among dengue-seronegative participants 2 to 16 years of age, the cumulative 5-year incidence of hospitalization for VCD was 3.06% among vaccine recipients and 1.87% among controls, with a hazard ratio (vaccine vs. control) through data cutoff of 1.75 (95% confidence interval [CI], 1.14 to 2.70). Among dengue-seronegative participants 9 to 16 years of age, the cumulative incidence of hospitalization for VCD was 1.57% among vaccine recipients and 1.09% among controls, with a hazard ratio of 1.41 (95% CI, 0.74 to 2.68). Similar trends toward a higher risk among seronegative vaccine recipients than among seronegative controls were also found for severe VCD. Among dengue-seropositive participants 2 to 16 years of age and those 9 to 16 years of age, the cumulative incidence of hospitalization for VCD was 0.75% and 0.38%, respectively, among vaccine recipients and 2.47% and 1.88% among controls, with hazard ratios of 0.32 (95% CI, 0.23 to 0.45) and 0.21 (95% CI, 0.14 to 0.31). The risk of severe VCD was also lower among seropositive vaccine recipients than among seropositive controls. CONCLUSIONS: CYD-TDV protected against severe VCD and hospitalization for VCD for 5 years in persons who had exposure to dengue before vaccination, and there was evidence of a higher risk of these outcomes in vaccinated persons who had not been exposed to dengue. (Funded by Sanofi Pasteur; ClinicalTrials.gov numbers, NCT00842530 , NCT01983553 , NCT01373281 , and NCT01374516 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
RUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Analysis of Incomplete Multivariate Data
Schafer, J. L. (1997) · doi:10.1201/9781439821862 · Cited by 6,012
van der Laan, M. J., Polley, E. C., & Hubbard, A. E. (2007) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1309 · Cited by 1,719
A case-cohort design for epidemiologic cohort studies and disease prevention trials
PRENTICE, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,439
Antibody-dependent enhancement of severe dengue disease in humans
Katzelnick, L. C., Gresh, L., Halloran, M. E., Mercado, J. C., Kuan, G., Gordon, A., Balmaseda, A., & Harris, E. (2017) · Science · doi:10.1126/science.aan6836 · Cited by 1,205
The global burden of dengue: an analysis from the Global Burden of Disease Study 2013
Stanaway, J. D., Shepard, D. S., Undurraga, E. A., Halasa, Y. A., Coffeng, L. E., Brady, O. J., Hay, S. I., Bedi, N., Bensenor, I. M., Castañeda-Orjuela, C. A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00026-8 · Cited by 1,124
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
Hadinegoro, S. R., Arredondo-García, J. L., Capeding, M. R., Deseda, C., Chotpitayasunondh, T., Dietze, R., Hj Muhammad Ismail, H. I., Reynales, H., Limkittikul, K., Rivera-Medina, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506223 · Cited by 1,077
Self-citationCapeding, M. R., Tran, N. H., Hadinegoro, S. R. S., Ismail, H. I. H. M., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61060-6 · Cited by 973
Self-citation
Research works printed but not linked: 4
- Mizumoto K, Ejima K, Yamamoto T, Nishiura H. On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling. J Vector Borne Dis 2014;51:153-164.25253207 · doi:10.4103/0972-9062.141704
- 10.1016/j.cmi.2018.01.018 · doi:10.1016/j.cmi.2018.01.018
- 10.1016/j.jviromet.2018.03.007 · doi:10.1016/j.jviromet.2018.03.007
- 10.1016/j.vaccine.2016.08.050 · doi:10.1016/j.vaccine.2016.08.050
Cited by
The continued threat of emerging flaviviruses
Pierson, T. C., & Diamond, M. S. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0714-0 · Cited by 1,098
The importance of vector control for the control and elimination of vector-borne diseases
Wilson, A. L., Courtenay, O., Kelly-Hope, L. A., Scott, T. W., Takken, W., Torr, S. J., & Lindsay, S. W. (2020) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0007831 · Cited by 874
Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
Wilder-Smith, A., Ooi, E.-E., Horstick, O., & Wills, B. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32560-1 · Cited by 692
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560
Looking beyond COVID-19 vaccine phase 3 trials
Kim, J. H., Marks, F., & Clemens, J. D. (2021) · Nature Medicine · doi:10.1038/s41591-021-01230-y · Cited by 585
Zimmermann, P., & Curtis, N. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320338 · Cited by 502
The Global Expansion of Dengue: How Aedes aegypti Mosquitoes Enabled the First Pandemic Arbovirus
Brady, O. J., & Hay, S. I. (2020) · Annual Review of Entomology · doi:10.1146/annurev-ento-011019-024918 · Cited by 405
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
Biswal, S., Reynales, H., Saez-Llorens, X., Lopez, P., Borja-Tabora, C., Kosalaraksa, P., Sirivichayakul, C., Watanaveeradej, V., Rivera, L., Espinoza, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903869 · Cited by 405
COVID-19 vaccines: rapid development, implications, challenges and future prospects
Kashte, S., Gulbake, A., El-Amin III, S. F., & Gupta, A. (2021) · Human Cell · doi:10.1007/s13577-021-00512-4 · Cited by 402
Current Understanding of the Pathogenesis of Dengue Virus Infection
Bhatt, P., Sabeena, S. P., Varma, M., & Arunkumar, G. (2021) · Current Microbiology · doi:10.1007/s00284-020-02284-w · Cited by 378
Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery
Maeki, M., Uno, S., Niwa, A., Okada, Y., & Tokeshi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.017 · Cited by 349
Paz-Bailey, G., Adams, L. E., Deen, J., Anderson, K. B., & Katzelnick, L. C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02576-x · Cited by 346
A review of Dengvaxia®: development to deployment
Thomas, S. J., & Yoon, I.-K. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1658503 · Cited by 331
Adaptive immune responses to primary and secondary dengue virus infections
St. John, A. L., & Rathore, A. P. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0123-x · Cited by 327
Wang, W.-H., Urbina, A. N., Chang, M. R., Assavalapsakul, W., Lu, P.-L., Chen, Y.-H., & Wang, S.-F. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.03.007 · Cited by 310
Zika virus infection enhances future risk of severe dengue disease
Katzelnick, L. C., Narvaez, C., Arguello, S., Lopez Mercado, B., Collado, D., Ampie, O., Elizondo, D., Miranda, T., Bustos Carillo, F., Mercado, J. C., et al. (2020) · Science · doi:10.1126/science.abb6143 · Cited by 271
Tricou, V., Yu, D., Reynales, H., Biswal, S., Saez-Llorens, X., Sirivichayakul, C., Lopez, P., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00522-3 · Cited by 268
Biswal, S., Borja-Tabora, C., Martinez Vargas, L., Velásquez, H., Theresa Alera, M., Sierra, V., Johana Rodriguez-Arenales, E., Yu, D., Wickramasinghe, V. P., Duarte Moreira, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30414-1 · Cited by 263
Immunization: vital progress, unfinished agenda
Piot, P., Larson, H. J., O’Brien, K. L., N’kengasong, J., Ng, E., Sow, S., & Kampmann, B. (2019) · Nature · doi:10.1038/s41586-019-1656-7 · Cited by 206
COVID 19 Vaccines: Should we fear ADE?
Halstead, S. B., & Katzelnick, L. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa518 · Cited by 69
Dengue in India: Towards a better understanding of priorities and progress
Shet, A., & Kang, G. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.03.008 · Cited by 21
Metadata
- Authors
- Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., Savarino, S., Zambrano, B., Moureau, A., Khromava, A., Moodie, Z., Westling, T., Mascareñas, C., Frago, C., Cortés, M., Chansinghakul, D., Noriega, F., Bouckenooghe, A., Chen, J., Ng, S.-P., Gilbert, P. B., Gurunathan, S., & DiazGranados, C. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-07-26
- Volume
- 379
- Issue
- 4
- Pages
- 327-340
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2807989886
- Cited by
- 783
- References
- 18
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.